Netherlands

Gilead Sciences is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Gilead’s operation in Amsterdam is responsible for medical, sales and marketing support for our products throughout the Netherlands.

Since 2013, the Dutch Transparency Register makes financial links between pharmaceutical manufacturers and professionals, institutions (including patient organizations) or joint ventures public. The information regarding the financial support of Gilead Sciences can be found in the Transparency Register (www.transparantieregister.nl).

However, the costs of research and development are not included in this transparency register. In order to make research and development costs as transparent as possible, EFPIA (European Federation of Pharmaceutical Industries and Associations) asked all member pharmaceutical companies to publish their research and development costs on their own websites (click here for the EFPIA Disclosure Code). The costs are made public on an aggregated basis in each reporting period. The disclosures are made on an annual basis and each reporting period covers a full calendar year (the 'reporting period').

The amount paid in 2023 is € 8.823.196,81.

Gilead Sciences provided support to patient organizations via sponsorship agreements or unrestricted grants.

The information regarding the financial support of Gilead Sciences to patient organizations can be found in the Transparency Register(www.transparantieregister.nl).

This page is intended for visitors outside of the United States.